 |
市場調查報告書
商品編碼
1621833
免疫調節劑市場機會、成長動力、產業趨勢分析與預測 2024 - 2032Immunomodulators Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年全球免疫調節劑市場價值為 2,177 億美元，預計 2024 年至 2032 年複合年成長率為 6.7%。自體免疫疾病、癌症和慢性感染等疾病。有幾個因素推動了市場的成長，包括自體免疫疾病和發炎性疾病的日益普及、生物技術和藥物研究的不斷進步以及對免疫調節療法的認知不斷增強。醫療保健支出的增加和對有效治療的需求不斷成長也促進了市場的擴張。此外，新冠肺炎後併發症的激增進一步加速了對免疫調節劑的需求，因為這些療法被用於管理長期呼吸問題和其他健康挑戰。
市場分為兩大產品類型：免疫抑制劑和免疫增強劑。免疫抑制劑在 2023 年佔據最大收入佔有率，為 1,365 億美元，預計在預測期內將穩定成長。隨著全球器官移植率持續上升，對器官移植藥物的需求增加推動了這一成長。免疫抑制劑在預防器官排斥和確保移植成功方面發揮著至關重要的作用。
按應用細分時，免疫調節劑市場包括腫瘤學、自體免疫疾病、傳染病和其他應用。 2023 年，腫瘤學領域引領市場，價值 854 億美元。免疫調節劑擴大用於癌症治療，以幫助增強免疫系統瞄準和破壞癌細胞的能力。這些療法包括免疫檢查點抑制劑、細胞激素和癌症疫苗，由於它們能夠改變免疫環境以更有效地對抗腫瘤，因此在現代腫瘤學中變得至關重要。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 2177 億美元 |
| 預測值 | 3,887 億美元 |
| 複合年成長率 | 6.7% |
預計北美將主導免疫調節劑市場，預計到 2032 年將達到 1,783 億美元。患有多種慢性病的人數不斷增加，顯著增加了該地區對免疫調節治療的需求，推動了市場成長和創新。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 自體免疫疾病和癌症的盛行率不斷增加
- 生物技術的進步
- 在慢性病管理中擴大採用生物製劑和生物相似藥
- 產業陷阱與挑戰
- 免疫調節療法相關的高成本
- 潛在的副作用和長期的安全性問題
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按產品類型，2021 - 2032 年
- 主要趨勢
- 免疫抑制劑
- 免疫增強劑
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 腫瘤學
- 自體免疫疾病
- 傳染病
- 其他應用
第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
- 其他最終用戶
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Biogen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- UCB SA
The Global Immunomodulators Market was valued at USD 217.7 billion in 2023 and is projected to grow at a CAGR of 6.7% from 2024 to 2032. Immunomodulators, which can either enhance (immunostimulants) or suppress (immunosuppressants) immune system activity, are essential for treating conditions such as autoimmune diseases, cancer, and chronic infections. Several factors drive the market growth, including the increasing prevalence of autoimmune and inflammatory diseases, ongoing advancements in biotechnology and pharmaceutical research, and a growing awareness of immunomodulatory therapies. Rising healthcare expenditures and the growing need for effective treatments also contribute to the market expansion. Additionally, the surge in post-COVID complications has further accelerated the demand for immunomodulators, as these therapies are being used to manage long-term respiratory issues and other health challenges.
The market is divided into two major product types: immunosuppressants and immunostimulants. Immunosuppressants, which accounted for the largest revenue share of USD 136.5 billion in 2023, are projected to grow steadily over the forecast period. This growth is driven by an increased demand for organ transplant medications as the global rate of organ transplants continues to rise. Immunosuppressants play a vital role in preventing organ rejection and ensuring transplant success.
When segmented by application, the immunomodulators market includes oncology, autoimmune diseases, infectious diseases, and other applications. The oncology segment led the market in 2023, valued at USD 85.4 billion. Immunomodulators are increasingly being used in cancer treatment to help strengthen the immune system's ability to target and destroy cancer cells. These therapies, which include immune checkpoint inhibitors, cytokines, and cancer vaccines, are becoming crucial in modern oncology for their ability to modify the immune environment to fight tumors more effectively.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $217.7 Billion |
| Forecast Value | $388.7 Billion |
| CAGR | 6.7% |
North America is expected to dominate the immunomodulators market, with projections reaching USD 178.3 billion by 2032. The U.S. generated USD 91.2 billion in 2023, primarily due to the high prevalence of chronic diseases. The growing number of individuals living with multiple chronic conditions is significantly increasing the demand for immunomodulatory treatments in the region, driving market growth and innovation.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°-degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of autoimmune diseases and cancer
- 3.2.1.2 Advancements in biotechnology
- 3.2.1.3 Growing adoption of biologics and biosimilars in chronic disease management
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High costs associated with immunomodulatory therapies
- 3.2.2.2 Potential side effects and long-term safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Immunosuppressants
- 5.3 Immunostimulants
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Oncology
- 6.3 Autoimmune diseases
- 6.4 Infectious diseases
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Amgen Inc.
- 9.3 AstraZeneca PLC
- 9.4 Biogen Inc.
- 9.5 Bristol-Myers Squibb Company
- 9.6 Eli Lilly and Company
- 9.7 F. Hoffmann-La Roche AG
- 9.8 Gilead Sciences, Inc.
- 9.9 Johnson & Johnson
- 9.10 Merck & Co., Inc.
- 9.11 Novartis AG
- 9.12 Pfizer Inc.
- 9.13 Sanofi
- 9.14 Teva Pharmaceutical Industries Limited
- 9.15 UCB S.A.
